Response Rate of Bevacizumab and FOLFOXIRI with pegfilgrastim in RAS-mutant type unresectable metastatic colorectal cancer. - Revital Trial

Kyoto University Hospital0 个研究点目标入组 40 人开始时间: 2015年7月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•1.Severe infection 2.Neuropathy >= Grade 2 according to the CTCAE 3.Prior hypersensitivity reaction to drugs useing in this trial 4.Dementia, altered mental status, or any psychiatric condition 5.Uncontrolled body fruid (ascites,pleural effusion.pericardiac effsion) 6.Severe stenotic primary lesion 7.Recieved radiotherapy to target lesion 8.Severe comorbidity (paralytic or mechanical bowel obstruction, interstitial pneumonia, pulmonary fobrosis, uncontrolable diabetes, heart failure,hypertension, renal failure, liver failure,thromboembolic disease, cerebrovascular disease, etc.) 9.Current or previous (within the last 1 year) history of GI perforation 10.HBs-Ag(+) 11.Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery except for CV-port procedure within 28 days 12.Active other malignant disease 13.Symptomatic brain metastasis 14.Uncontroled severe diarrhea 15.Past chemotherapy history by cytotoxic agent for other diseases except hormone agents and molecular target drugs 16.Women's pregnant or nursing, men/women who want to give birth or no intention to contraception 17.Any other cases who are regarded as inadequate for study enrollment by investigators.

发起方